# Trident SAP 20:10 Science-based omega-3 fish oil of exceptional purity for optimal health

especially omega-3 fatty acids. Since omega-6 fatty acids tend to be predominant in the western diet, supplementing with omega-3 fatty acids helps to mediate inflammatory pathways and maintain cell structure, fluidity, and function. Although there are several sources of omega-3 fatty acids available through a regular diet containing protein, plant oils, seeds, and nuts, fish oil is naturally able to provide a 2:1 ratio of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) respectively, a ratio that has been used in majority of clinical trials and shown various health benefits. Due to their anti-inflammatory function, omega-3 fatty acids are beneficial in reducing the risk of cardiovascular diseases such as arrhythmias, hyperlipidemia, and thrombosis. Supplementation with EPA and DHA can improve symptoms of autoimmune diseases such as rheumatoid arthritis and asthma. DHA deficiency has been associated with impaired neurotransmission and synaptic activity, due to which DHA has been recommended for fetal development and through infancy. Omega-3 supplementation, especially EPA and DHA, can vastly improve reproductive health in men and women.

Trident SAP 20:10 provides the optimum dose and ratio of EPA and DHA in triglyceride form (TG) for overall maintenance of good health.

## ACTIVE INGREDIENTS

#### Each teaspoon contains:

Fish oil . . . 5 ml From wild deep-sea fish oil: sardine (*Clupeidae*; whole) and/or anchovy (*Engraulis encrasicolus*; whole). Molecularly distilled and/or supercritical CO2 extracted. Providing:

Eicosapentaenoic acid (EPA). ...790 mg 

Other ingredients: Rosemary extract, mixed tocopherols, ascorbyl palmitate, and natural lemon oil.

Contains no: Gluten, soy, wheat, corn, eggs, dairy, yeast, preservatives, artificial colours and flavours, starch, or sugar.

#### This product is non-GMO.

Trident 20:10 SAP contains 240 ml per bottle.

#### **DIRECTIONS FOR USE**

Adults: See indication-specific dosages outlined in the indication-specific dosage table.

Children and adolescents 1-13 years: Take 1 teaspoon once daily or as directed by your healthcare practitioner.

Adolescents and adults 14-18 years: Take 2 teaspoons once daily or as directed by your healthcare practitioner.

Adults 19 years and older: Take 2 to 4 teaspoons once daily or as directed by your healthcare practitioner.

## INDICATIONS

#### Trident SAP 20:10 can help:

- Promote cardiovascular health and improve inflammatory response.
- Support cognitive and mental health.
- Foster male and female reproductive health.
- Enhance development and function of brain, eyes, and nerves.
- Mitigate symptoms of autoimmune disorders such as multiple sclerosis and rheumatoid arthritis.

Refrigerate after opening and use within 60 days.

Do not use if seal is broken. Keep out of reach of children.

#### **PURITY, CLEANLINESS, AND STABILITY**

All ingredients listed for each Trident SAP 20:10 lot number have been tested by an ISO 17025 accredited third-party laboratory for identity, potency, and purity.

Each lot of Trident SAP 20:10 is tested for PCBs, dioxins, heavy metals, oxidative stability, and microbiological quality. Trident SAP 20:10 contains a proprietary antioxidant blend to ensure freshness and oxidative stability.



351, Rue Joseph-Carrier, Vaudreuil-Dorion, Quebec, J7V 5V5 T 1 866 510 3123 • F 1 866 510 3130 • nfh.ca

For healthcare professional use only.

Scientific Advisory Panel (SAP): adding nutraceutical research

to achieve optimum health

#### WHAT ARE OMEGA-3 FATTY ACIDS?

Omega-3 fatty acids are long-chain polyunsaturated fatty acids and are considered essential fatty acids because they cannot be synthesized by humans, thus must be obtained from the diet.[1] Fish and other marine life are rich sources of a special class of long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).<sup>[1]</sup> Plant food and vegetable oils, such as flaxseed, canola, and soybean oil, lack EPA and DHA; however, they do contain the intermediate-chain omega-3 fatty acid α-linolenic acid (ALA). Over the last few decades, numerous health benefits have been attributed to the consumption of the omega-3 fatty acid family, ALA, EPA, and DHA.<sup>[1]</sup>

#### THE OMEGA-6-TO-OMEGA-3 BALANCE

The contemporary Western diet is high in omega-6 fatty acids (omega-6 FAs) and deficient in omega-3 fatty acids (omega-3 FAs).<sup>[2]</sup> This ultimately leads to an imbalance in the cellular concentration of omega-6-to-omega-3 FAs. Although omega-3 FAs are structurally and functionally distinct from the omega-6 FAs, each is metabolized competitively to form eicosanoids, such as thromboxanes (TX), prostaglandins (PG), and leukotrienes (LT).<sup>[2][3]</sup> Eicosanoids have hormone-like effects and play an important role in cellular activity. Arachidonic acid (AA), a long-chain omega-6 FA, is the precursor for the harmful eicosanoids that promote inflammation (PGE<sub>2</sub>, LTB<sub>4</sub>), and stimulate platelet aggregation (TXA<sub>2</sub>).<sup>[3][4]</sup> Conversely, EPA is the precursor for the anti-inflammatory and antiaggregatory eicosanoids PGE<sub>3</sub>, LTB<sub>5</sub>, and TXA<sub>3</sub>. By increasing omega-3 FA intake, EPA and DHA are incorporated into cell-membrane phospholipids at the expense of AA, and a balance between the omega-6 and omega-3 FAs is returned, thus promoting healthy cellular structure, fluidity, and activity.<sup>[3][4][5]</sup>

#### **RECOMMENDED OMEGA-3 INTAKES**

Healthy Adults: <sup>[6]</sup>
Fish oil
Coronary Disease Patients: <sup>[7]</sup>
EPA+DHA ~1 g/d
Hypertriglyceridemia: <sup>[7]</sup>
EPA+DHA 2–4 g/d
Neurological Disorders: <sup>[8]</sup>
EPA
Inflammatory Disorders (rheumatoid arthritis): <sup>[4]</sup>
EPA+DHA 3 g/d

#### SAFETY OF OMEGA-3 SUPPLEMENTATION

In 2012 the European Food Safety Authority has advised that a dose of up to 5g/day of EPA and DHA for a period of 16 weeks in supplement form is considered safe for adults and not associated with any lipid peroxidative changes or adverse events in relation to CVD risk. Omega-3 FAs are thus safe and well-tolerated, and can be taken with a wide variety of other supplements.<sup>[7][10]</sup> Since omega-3 FAs are natural blood thinners, patients taking high dosages of aspirin or medicinal blood thinners should consult their healthcare professional before use.[10]

#### NATURAL RATIO AND FORM

The majority of scientific literature that reports the health benefits of omega-3 FAs is based on fish-oil research in which the oils provide their natural fatty acid ratios and form.<sup>[11]</sup> Fish oils are most commonly available in a standard 18:12 ratio (18% EPA and 12% DHA) or a concentrated 2:1 ratio, and supplied in triglyceride or ethyl ester form. Both triglyceride and ethyl ester forms are highly bioavailable and stable.[11]

#### **OMEGA-3 FATTY ACIDS AND NUTRITION RESEARCH**

#### Cardiovascular Disease

Main mechanisms through which EPA and DHA reduce the risk of cardiovascular disease (CVD) and sudden death include reduction in malignant ventricular arrhythmias, suppression of blood clotting and atherosclerosis, improvement in arterial wall tone, and anti-inflammatory effects.<sup>[1][12]</sup> Intake of 1 g/day of EPA+DHA in CVD patients can exert antiarrhythmic, hypolipidemic and antithrombotic effects, and at least 500 mg/day in patients without CVD can have cardioprotective effects.<sup>[13]</sup>

#### Inflammation and Autoimmune Diseases

EPA and DHA have important implications in the prevention and treatment

# **Research Monograph**

of chronic inflammatory conditions, such as rheumatoid arthritis and asthma.<sup>[3]</sup> EPA produces the eicosanoids PGE<sub>3</sub> and LTB<sub>5</sub>, which reduce the duration and intensity of inflammation. DHA reduces transcription of the proinflammatory cytokines, interleukin 1B, and tumour necrosis factor-a, C-reactive protein (CRP), serum amyloid A.<sup>[3][4]</sup> New scientific evidence suggests that intake of fish oils may reduce rheumatoid arthritis risk and positively impact blood lipid profile in rheumatoid arthritid patients.

#### Cancers of the Breast, Prostate, and Colon

Both epidemiological and experimental evidence that the omega-3 FAs EPA and DHA may reduce the risk of breast, colon, and prostate cancer.<sup>[5]</sup> The possible chemoprotective mechanisms through which fish oils act are suppression of neoplastic transformation, cell-growth inhibition, and enhanced apoptosis and antiangiogenicity.<sup>[5]</sup> These biological effects are associated with the inhibition of omega-6 FAs (AA)-derived eicosanoids during omega-3 FA supplementation.<sup>[5][15]</sup>

#### **Central Nervous System Health and Mental Disorders**

The central nervous system (CNS) is highly concentrated with long-chain fatty acids, specifically DHA and AA. A deficiency of DHA markedly affects neurotransmission, membrane-bound enzymes and ion channel activities, gene expression, intensity of inflammation and immunity, and synaptic plasticity.[16] Increased intake of fish oils may help to improve signal transduction processes and reduce neuronal changes, symptoms and risk of schizophrenia, depression, stroke, and Alzheimer's disease.[16] During pregnancy and lactation, DHA supplementation is crucial for optimal fetal neuronal development and visual acuity through to infancy.<sup>[6]</sup>

#### **Sexual and Reproductive Health**

Recent evidence from clinical trials has shown positive effects of omega-3 fatty acids on reproductive health in men and women. A prospective cohort study of 100 women undergoing assisted reproductive techniques (ART) showed a positive association between serum long chain omega-3 fatty acid levels and probability of live birth.<sup>[17]</sup> Supplementation of 1500 mg per day of omega-3 fatty acids for 6 months improved insulin resistance and hirsutism in PCOS patients.<sup>[18]</sup> A significant improvement in seminal antioxidant status and reduced sperm DNA fragmentation was observed in participants supplemented with 1500 mg of DHA enriched oil for 10 weeks.

#### REFERENCES

- Holub, B.J. "Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care." Canadian Medical Association Journal Vol. 166, No. 5 (2002): 608–615.
- Simopoulos, A.P. "An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity." 2. Nutrients. Vol. 8, No. 3 (2016): 1-17. Calder PC. "Omega-3 fatty acids and inflammatory processes: from molecules to man." Biochem Soc
- 3. Trans. Vol 45, No.5 (2017):1105-1115. Gioxari, A., Kaliora A.C., Marantidou F., Panagiotakos D.P. "Intake of omega-3 polyunsaturated fatty
- acids in patients with rheumatoid arthritis: a systematic review and meta-analysis." Nutrition. Vol. 45 (2018):114-124
- Abel, S., S. Riedel, and W.C. Gelderblom. "Dietary PUFA and cancer." The Proceedings of the Nutrition 5. Society, Vol. 73, No. 3 (2014): 361–367. Simopoulos, A.P. "Omega-3 fatty acids and athletics." Curr Sports Med Rep. Vol. 6 No. 4 (2007):230-6.
- Kris-Etherton, P.M., W.S. Harris, and L.I. Appel: AHA Nutrition Committee, American Heart Association. "Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association." Arteriosclerosis, Thrombosis, and Vascular Biology Vol. 23, No. 2 (2003): 151–152.
- Gören, J.L., and A.T. Tewksbury. "The use of omega-3 fatty acids in mental illness." Journal of Pharmacy Practice. Vol. 24, No. 5 (2011): 452–471. 9.
- EFSA 2012: European Food Safety Authority. "Scientific opinion: Scientific opinion on the tolerable upper level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal. Vol. 10, No. 7 (2012):2815
- Tajuddin, N., A. Shaikh, and A. Hassan. "Prescription omega-3 fatty acid products: Considerations for patients with diabetes mellitus." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Vol. 9 (2016): 109-118.
- 11. Dyerberg, J., et al. "Bioavailability of marine n-3 fatty acid formulations." Prostaglandins, Leukotrienes
- Dependency, J., et al. Diodentiality of manner in Tarky act infinitions. Prostagranding, Economics and Essential Fatty Acids. Vol. 83, No. 3 (2010): 137–141.
  Jones, P.J., and V.W. Lau. "Effect of n-3 polyunsaturated fatty acids on risk reduction of sudden death." *Nutrition Reviews*. Vol. 60, No. 12 (2002): 407–409.
  von Schacky, C. "Omega-3 index and sudden cardiac death." *Nutrients*. Vol. 2, No. 3 (2010): 375–388.
  Khawaja, O.A., J.M. Gaziano, and L. Djousse. "n-3 Fatty acids for prevention of cardiovascular disease." *Current Atherosclerosis Reports*. Vol. 16, No. 11 (2014): 1–7.
- Guz, Z., et al. "n-3 Polyunsaturated fatty acids and their role in cancer chemoprevention." Current Pharmacology Reports. Vol. 1, No. 5 (2015): 283–294.
- 16. Weiser, M.J., C.M. Butt, and M.H. Mohajeri. "Docosahexaenoic acid and cognition throughout the lifespan." Nutrients. Vol. 8, No. 2 (2016): 1–40.
- 17. Chiu Y.H., Karmon A.E., Gaskins A.I., Arvizu M., Williams P.L., Souter J., Rueda B.R., Hauser R., Chavarro I.E., EARTH Study Team. "Serum omega-3 fatty acids and treatment outcomes among women undergoing assisted reproduction." Hum Reprod. Vol. 33, No. 1 (2018):156-165.
- Oner G., Muderris I.I. "Efficacy of omega-3 in the treatment of polycystic ovary syndrome." J Obstet Gynaecol. Vol. 33, No. 3 (2013):289-91.
- Martinez-Stot J.C., Domingo J.C., Cordobilla B., Nicolas M., Fernandez L., Albero P., Gadea J., Landeras J. "Dietary supplementation with docosahexaenoic acid (DHA) improves seminal antioxidant status and decreases sperm DNA fragmentation."Syst Biol Reprod Med. Vol. 62, No. 6 (2016):387-395.

## **Trident SAP 20:10** Science-based omega-3 fish oil of exceptional purity for optimal health



## INDICATION SPECIFIC DOSAGE SUMMARY BASED ON HUMAN CLINICAL RESEARCH#

<sup>#</sup>Please note these suggestions are guidelines based on the clinical studies. Evidence for efficacy and safety have been qualitatively (study quality in terms of study design, sample size, appropriate methods of analysis, use of appropriate placebo/control, bias etc) assessed and have been rated using a 5 star <del>\*</del> rating classification.

Indication	Suggested Dosage	Supporting evidence and study outcomes	Study design	Outcomes measures/ selection criteria for studies	Safety	Evidence quality rating	
Cardiovascular Health							
Cardiovascular disease <sup>1</sup>	Children and adolescents 1-17 years - 1/2-1 tsp per day. Adults 18 years and older - 1 tsp per day	Reduction of triglycerides, systolic blood pressure, diastolic blood pressure, heart rate, C-reactive protein. Increase in LDL and HDL	171 clinical trials (total n not available), dose range EPA+DHA 180-15000 mg/day, duration range 4-240 weeks. Recommended intake - 250-500 mg/ day EPA+DHA	Lipid profile - total cholesterol, low density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), blood pressure, C-reactive protein, other inflammatory markers	No adverse events	***	
Cardiovascular health and inflammation <sup>2</sup>	Adults: 2-4 tsp per day	Higher EPA:DHA ratio associated with decrease in CRP	92 randomized, placebo-controlled trials. Studies included used dose between 2 g-6 g	Total cholesterol, LDL, HDL, TG, blood pressure, heart rate, CRP	No adverse events	****	
Cognition and Mental Health							
Depression <sup>3</sup>	Children 1–11 years - 1 tsp per day Adolescents 12–17 years - 2 tsp per day Adults 18 years and older - 2 tsp per day	Reduction in depression scores in trials using EPA+DHA, with EPA ≥ 60%, compared to trials using EPA alone	15 randomized controlled trials (n=916), dose (avg. 10 trials) EPA+DHA, with EPA ≥ 60% for (avg. 10 trials), duration 11 weeks)	Depression outcomes (Hamilton Depression Rating Scale, Beck Depression Inventory, Montgomery– Asberg Depression Scale, Childhood Depression Rating Scale, Depression, Anxiety, and Stress Scale)	No adverse events	***	
Psychomotor and visual development <sup>4</sup>	Pregnant mothers - 1 tsp per day	Improvement in visual acuity, mental and psychomotor development indexes	38 trials (n=5541 - mothers, preterm, and term infants), avg. DHA dose 673 ± 547 mg/day, EPA dose 297 ± 512 mg/ day, avg. duration 22 weeks	Bayley Scales of Infant Development mental and psychomotor developmental indexes, intelligence quotient (IQ), visual acuity	No adverse events	***	



#### **Reproductive Health** Male fertility<sup>5</sup> Adult men - 1 tsp Improvement of 3 randomized Semen quality -No sperm motility. controlled trials volume, sperm per dav adverse concentration of (n=281), dose avg. concentration. events 968 mg/day for avg. DHA in seminal morphology, motility, duration 19 weeks **DNA** fragmentation plasma \*\*\* Improved HOMA 9 randomized Homeostatic model Female Adult women - 2 Mild index, reduced controlled trials reproductive tsp per day of assessment adverse levels of TG and (n=591), dose avg. of 8 health - PCOS<sup>6</sup> (HOMA), TG. events adiponectin, insulin total cholesterol. studies 1600 mg/day in 1 increase in for avg. duration 12 resistance, total study adiponectin levels weeks cholesterol **Autoimmune Disorders** Multiple Adults with MS Improvement 7 clinical trials MS quality of life \*\*\*\* No sclerosis (MS)<sup>7</sup> in inflammatory (n=240914), dose questionnaires, diagnosis - 3-4 adverse tsp per day markers, recommended 4 g/ dietary habits, events day of omega-3 or fish glutathione inflammatory markers, blood cell reductase, oil, duration avg. 6-12 reduced relapse months for 5 studies. profile. glutathione reductase levels rate, healthy 30 months for one omega-6:omega -3 study, and 1980-2007 for long term study ratios Rheumatoid Adults with RA Improvement 20 randomized. Early morning $\star \star \star$ No arthritis<sup>8</sup> diagnosis - 3-4 of 8 disease controlled trials stiffness, swollen adverse count, tender joint tsp per day biomarkers. (n=1252), duration events reduced 12-72 weeks, omega-3 count, patient and leukotriene fatty acids ≥3 g/d had physician global B4, and an impact on global assessment, pain improved blood assessment. duration scale, disease triacylglycerol ≥3 months assessment, fatigue, levels body weight.

## C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF- $\alpha$ )

#### **References:**

- 1. AbuMweis S., et al. "Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a metaanalysis of randomised placebo-control human clinical trials." J Hum Nutr Diet. Vol. 84, No. 1 (2018 Feb): 31-67.
- 2. AbuMweis S., et al. "The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials." *Complement Ther Med.* (2021 Mar): 57-102662.
- 3. Sublette M.E., et al. "Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression." J Clin Psychiatry. Vol. 84, No. 12 (2011 Dec): 72-1577.
- 4. Shulkin M., et al. "n-3 Fatty Acid Supplementation in Mothers, Preterm Infants, and Term Infants and Childhood Psychomotor and Visual Development: A Systematic Review and Meta-Analysis." J Nutr. Vol. 418, No. 3 (2018 Mar 1): 148-409.
- 5. Hosseini B., et al. "The Effect of Omega-3 Fatty Acids, EPA, and/or DHA on Male Infertility: A Systematic Review and Meta-analysis." J Diet Suppl. Vol. 256, No. 2 (2019): 16-245.
- 6. AlAmmar W.A., et al. "Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review." *Nutr Neurosci*. Vol. 579, No. 7 (2021 Jul): 24-569.
- Gioxari A., et al. "Intake of ω-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A systematic review and meta-analysis." Nutrition. Vol. 124 (2018 Jan): 45-114.
- 8. Yang K., et al. "Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis." *Reprod Biol Endocrinol.* No. 1 (2018 Mar 27): 16-27